Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Teriparatide Pen Injector [Forteo]

 
National Institutes of Health

Related topics

Related topics

3 relations

Narrower (1)

28 ACTUAT Teriparatide 0.02 MG/ACTUAT Pen Injector [Forteo]
ForteoPen Injector

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Efficacy and Safety of the Biosimilar Recombinant Human Parathyroid Hormone Cinnopar® in Postmenopausal Osteoporotic Women: A Randomized Double-blind Clinical Trial
Background: Due to high cost and burden of osteoporosis, it is reasonable to focus on the reduction of fractures as the main goal… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
2016
2016
Utilization and cost of anti-osteoporosis therapy among US Medicare beneficiaries
SummaryThere is a strong impetus to prevent and treat osteoporosis to prevent fractures. $990 million dollars was spent on anti… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Review
2009
Review
2009
Of mice and men: divergent risks of teriparatide-induced osteosarcoma
SummarySince approval by the U.S. Food and Drug Administration (FDA) in December 2002, teriparatide (recombinant 1-34 PTH; Forteo… Expand
  • figure 1
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE